Clinical Trials
Parasol Dry AMD/Geographic Atrophy (81201887MDG2001) [Enrollment Closed]
Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial To Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Gather2 ISEE2008 – Iveric Bio [Enrollment Closed]
A Phase 3, multicenter, randomized, double-masked shamcontrolled clinical trial to assess the safety and efficacy of intravitreal administration of Zimura (complement C5 inhibitor) in patients with Geographic Atrophy secondary to Age-Related Macular Degeneration
Burgundy BP41670 – Genentech [Enrollment Open]
A Three-part, Phase I Study To Investigate The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Zifibancimig Following Intravitreal Administration Of Multiple Ascending Doses And Continuous Delivery From The Port Delivery In Patients With Neovascular Age-related Macular Degeneration.
Atmosphere – RGX-314-2104 – REGENXBIO [Enrollment Open]
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
Lugano – Eyepoint [Enrollment Open]
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, A Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD
4Front-1 – 4D Molecular Therapeutics [Upcoming Trial]
The trial objective is to evaluate the efficacy, safety, and durability of a single intravitreal (IVT) injection of 4D-150 (3 ×10¹⁰ vector genomes [VG]) compared with aflibercept (2 mg IVT) every 8 weeks (Q8W) in adults with nAMD. The primary efficacy objective is to demonstrate non-inferiority of a single injection of 4D-150 to aflibercept (Q8W) in the mean change in BCVA from baseline to week 52.
Rioja – Eyebio [Enrollment Open]
A phase 1/2a 2-part study consisting of an open-label multiple ascending dose (MAD) safety study in participants with macular edema following branch retinal vein occlusion (BRVO), and a dose-finding, double-masked, comparative safety and preliminary efficacy study of intravitreal (IVT) EYE201 (Tiespectus) in participants with either diabetic macular edema (DME) or neovascular age-related macular degeneration (nvAMD).
Shore – OPT-302-1004 – OPTHEA [Enrollment Closed]
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
EYE103-101 DME & Wet AMD [Enrollment Closed]
A 2-part study consisting of an open-label multiple ascending dose (MAD) safety study, and a dose-finding single-masked comparative safety and preliminary efficacy study of intravitreal (IVT) EYE103 in a mixed population of participants with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD)
Dream Diabetic Retinopathy (OTT166-201) [Enrollment Closed]
A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)
TENAYA – GR40306 – Genentech Roche [Trial Completed]
A Phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety faricimab in patients with neovascular age-related macular degeneration.
Pavilion GR41675 – Genentech – Roche [Enrollment Closed]
A Phase III, Multicenter, Randomized study of the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranizumab in patients with Diabetic Retinopathy
Condor: CRTH258D2301 – Novartis [Trial Completed]
Novartis pharmaceuticals trail entitled: A 96-week, two-arm, randomized single-masked, multi-center, Phase III study assessing the efficacy and safety of Brolucizumab 6mg compared to Panretinal Photocoagulation Laser in patients with Proliferative Diabetic Retinopathy.
Balaton – GR41984 – Genentech – Roche [Trial Completed]
A Phase III, Multicenter, Randomized, Double-Masked, Active comparator – controlled study to evaluate the efficacy and safety of Faricimab in patients with Macular Edema secondary to Branch Retinal Vein Occlusion
Rivoli CRVO BP44241 [Enrollment Open]
A phase IB, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to investigate the biological activity, safety, tolerability, pharmacokinetics and pharmacodynamics of ro7200394 in participants with macular edema secondary to central retinal vein occlusion
Comino- GR41986 – Genentech – Roche [Trial Completed]
A Phase III, Multicenter, Randomized, Double-Masked, Active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with Macular Edema secondary to Central Retinal or Hemiretinal Vein Occlusion.
Brunello – Eyebio [Enrollment Open]
A randomized, double-masked, multi-center, 3-arm pivotal phase 2/3 study to evaluate the efficacy and safety of intravitreal EYE103 compared with intravitreal ranibizumab (0.5 mg) in participants with diabetic macular edema.
Thames – Genentech [Enrollment Open]
Phase I/II to evaluate the safety and tolerability, pharmacokinetics, and efficacy of RO7446603 administered alone or in combination with aflibercept or faricimab in patients with diabetic macular edema.
Rioja – Eyebio [Enrollment Open]
A phase 1/2a 2-part study consisting of an open-label multiple ascending dose (MAD) safety study in participants with macular edema following branch retinal vein occlusion (BRVO), and a dose-finding, double-masked, comparative safety and preliminary efficacy study of intravitreal (IVT) EYE201 (Tiespectus) in participants with either diabetic macular edema (DME) or neovascular age-related macular degeneration (nvAMD).
Barolo – Eyebio [Enrollment Open]
A randomized, double-masked, multicenter, 3-arm pivotal phase 2/3 study to evaluate the efficacy and safety of intravitreal EYE103 compared with intravitreal ranibizumab (0.5 mg) in participants with diabetic macular edema.
Insite 2022-01 – McMaster University [Enrollment Closed]
Treat & Extend versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
EYE103-101 DME & Wet AMD [Enrollment Closed]
A 2-part study consisting of an open-label multiple ascending dose (MAD) safety study, and a dose-finding single-masked comparative safety and preliminary efficacy study of intravitreal (IVT) EYE103 in a mixed population of participants with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD)
Protocol GR43828 (DME Study) [Enrollment Closed]
A Phase I, Multicenter, Open-label study of the safety, tolerability, pharmacokinetics, and immunogenicity of intravitreal injections of RO7446603 alone and co-administered with aflibercept in patients with Diabetic Macular Edema.
Elevatum- Genentech Roche [Enrollment Closed]
A Phase IIIB/IV, Multicenter, Open-label, Single-arm study to investigate Faricimab (ro6867461) treatment response in treatment-naïve, underrepresented patients with diabetic macular edema.
Pagoda GR40550 – Genentech Roche [Enrollment Closed]
A Phase III, Multicenter, Randomized, visual assessor masked, active comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with Ranibizumab in patients with Diabetic Macular Edema.
Rhone-X GR41987 – Genentech – Roche [Trial Completed]
A Multicenter, open-Label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with Diabetic Macular Edema.
YOSEMITE – GR40349- Genentech Roche [Trial Completed]
A Phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema.
COOL-3 – RecensMedical Inc [Trial Completed]
A Randomized, Masked, Controlled Trial Studying the Use of Rapid Cooling Anesthesia for Local Anesthesia among Patients Receiving Intravitreal Injections.
- Diabetic Retinopathy in HIV Subjects Treated with EGRIFTA
- Treatment for center-involved DME in Eyes with Very Good Visual Acuity
- Short-term Evaluation of Combination Corticosteroid + Anti-VEGF Treatment for Persistent Central-involved Diabetic Macular Edema Following Anti-VEGF Therapy in Pseudophakic Eyes
- Lucentis – Avastin Trial Design
- Protocol “L”: Evaluation of Visual Acuity Measurements in Eyes with Diabetic Macular Edema
- Protocol “N”: An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage due to Proliferative Diabetic Retinopathy
- Mild Macular Grid (MMG) for Diabetic Macular Edema
- Steroid Injection for Diabetic Macular Edema
- Vitrectomy for Diabetic Macular Edema
- Peribulbar Triamcinolone
- PRP for Diabetic Macular Edema
- Subclinical Diabetic Macular Edema
- Anecortave Acetate for Wet AMD
- Anecortave Acetate for Dry AMD
- Surgical Therapeutics for Epiretinal Membranes and Vitrectomy
- Branch Vein Occlusion Sheathotomy Study
- Vit 100 (VitrenAse) Study for PVR
- Oral treatment of Diabetic Retinopathy (Lilly)
- Photodynamic Therapy (PDT) Study – Approved by FDA 4/2000
- Macular Translocation for CNV
- Perfluoron (PFO) Phase IV Clinical Trial
- Submacular Surgery Pilot Trials (SST)
- Perfluoron Study (PFO)
- Syntex Ganciclovir Implant Trials
- ISIS CMV Retinitis Trials
- RPE Transplantation Study
- Collaborative Ocular Melanoma
- COMS
- Macular Photocoagulation Study (MPS)
- IOP Vitrectomy Study
- Age-Related Eye Disease Study
- Richard-James Silicone Oil Study
- Vitrectomy for Macular Hole Study
- Endophthalmitis Vitrectomy Study (EVS)
- Advanced ROP Study
- SCORE2 – NIH (National Eye Institute) 2014 – 2016
For study inquiries please contact:
Diana A. CCRC, COT
Senior Clinical Research Coordinator
[email protected]
713-357-4976